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Abstract
Objective Coumarin anticoagulants are prone to poten-
tially life-threatening drug-drug interactions due to a
combination of unfavorable properties. However, real life
data on the actual occurrence are scarce. The aim of this
study was to quantify and qualify potential drug interac-
tions with coumarin anticoagulants in daily practice.
Methods A cohort study including all users of phenpro-
coumon or acenocoumarol during the period 1991–2003 in
the PHARMO Record Linkage System. All 24 individual
drugs and 11 drug groups interacting with coumarins
according to central database used in the Dutch pharmacies
were considered.
Main outcome measure Frequency and type of potential
drug interactions during anticoagulant therapy with cou-
marins.
Results 48,627 out of 76,455 mainly acenocoumarol-users
(64%) were dispensed at least one potentially interacting
drug (PID) during anticoagulant therapy. About 35% of these
cases were dispensed a (very) strongly interacting drug,
whereas 3% were dispensed a contraindicated drug.
Antibacterial drugs and NSAIDs (39% and 37% of all users,
respectively) were the most frequently dispensed PIDs.
Conclusion Potential drug interactions with coumarins
frequently occur in daily practice, confronting two-thirds of
patients with an increased risk of bleeding. To a large part,
this is attributable to commonly prescribed medication like
antibacterial drugs and NSAIDs. This situation substantiates
the need for proper monitoring or new anticoagulants with
less drug–drug interactions.
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Impact of findings on practice
• Potential drug interactions occur in two-thirds of
patients using coumarins.
• Pincipal interactions concern the commonly prescribed
anti-bacterial drugs and NSAIDs.
• The high potential for drug interactions of coumarins
puts patients at increased risk of bleeding, and costs
time and Money.
Introduction
Coumarin anticoagulants (i.e. acenocoumarol, phenpro-
coumon and warfarin) are extensively used for the treat-
ment and long-term prevention of thromboembolic
diseases [1]. These drugs induce anticoagulation by
antagonizing vitamin K, thereby impairing the biologic
activity of the vitamin-K dependent coagulation factors
(factor II, VII, IX, and X) [2, 3]. Apart from their benefit,
coumarin anticoagulants are prone to potentially life
threatening drug-drug interactions due to: (i) high protein
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binding; (ii) cytochrome P450 dependent metabolism; and
(iii) a narrow therapeutic range [2, 4].
In the Netherlands, a routine screening for potential
interactions is implemented in all pharmacies. Before drugs
are dispensed to the patients, potential interactions have to
be detected by the automated computer system. The entire
list of drugs which are supposed to interact with coumarins
comprises about 200 different compounds (Z-Index BV,
The Hague, The Netherlands, URL: http://www.z-in-
dex.nl). Some of these potentially interacting drugs (PIDs)
are not allowed to be dispensed to the patient, but should be
substituted with another drug. However, the majority of the
PIDs can be normally dispensed to the patient after the
anticoagulation clinic and/or the patient have been
informed (Dutch standard on coumarin interactions;
available through the internet via URL: http://www.fnt.nl).
Patients on coumarins who are dispensed a PID, are
confronted with an increased risk of bleeding or
thromboembolism. In addition, the effectiveness of the
interacting drug may be hampered.
Aim of the study
To date, ‘‘real life’’ data on the occurrence of potential
drug interactions with coumarins are scarce [5]. Therefore,
we performed a cohort study to quantify and qualify




Data were obtained from the PHARMO Record Linkage
System, which includes, among other databases, the
drug-dispensing records from community pharmacies and
hospital discharge records of more than 1 million com-
munity-dwelling inhabitants of 40 demographically defined
areas in The Netherlands. For all residents, the computer-
ized drug-dispensing histories contain data concerning the
dispensed drug, type of prescriber, dispensing date, dis-
pensed amount, prescribed dose regimens, and the legend
duration of use (prescription length). All drugs are coded
according to the Anatomical Therapeutic Chemical (ATC)
Classification. The hospital records include detailed infor-
mation concerning the primary and secondary diagnoses,
procedures, and dates of hospital admission and discharge.
All diagnoses are coded according to the International
Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). For a detailed description of the
database, which is representative for the Dutch population,
we refer to previous work [6].
Study cohort
The study population included all users of phenprocoumon
(ATC-code B01AA04) or acenocoumarol (ATC-code
B01AA07) in the period 1991–2003. No other coumarins
are available at the Dutch market. All patients were
followed from the first dispensing in the period 1991–2003
until the last dispensing, or the end of follow-up (October
1, 2004), whichever event was earliest.
Potential drug–drug interactions
All 24 individual drugs and 11 drug groups interacting with
coumarins according to the current Z-index database, the
central database used in the Dutch pharmacies (Z-Index
BV, The Hague, The Netherlands, URL: http://www.
z-index.nl), were considered for this study. For all PIDs,
relevance was classified into five categories according to
the Dutch standard on coumarin interactions (available
through the internet via URL: http://www.fnt.nl). Category
1 included all contraindicated drugs that very strongly
interact with coumarins and may not be used together with
coumarins. Category 2 comprised all very strongly inter-
acting drugs for which a substitute is lacking and that
necessitate intensive monitoring of anticoagulation.
Category 3 included all strongly interacting drugs that
preferably are substituted or otherwise necessitate intensive
monitoring of anticoagulation. Category 4 encompassed all
drugs that moderately or indistinctly interact with couma-
rins. Category 5 included all drugs that do not influence the
intensity of the anticoagulant effect of coumarin antico-
agulants, but increase the risk of bleeding by interfering
with hemostasis or by their ulcerogenic effect.
To study the frequency of potential drug interactions
during anticoagulant therapy with coumarins, treatment
episodes of coumarins during follow-up were established
for each patient, based on the method of Catalan [7]. In
general, a treatment episode is defined as a period of time
in which a continuous specific pharmacotherapeutic treat-
ment takes place. Coumarin treatment was considered to be
uninterrupted if the gap between the start of two consec-
utive dispensings was less than 180 days. A treatment
episode was measured as the time span between the starting
date of the first dispensing and the expiry date of the final
dispensing. The latter was set at the average duration time
after the last dispensing date. Patients may have had more
than one treatment episode of coumarins.
For each PID and PID group, the number of dispensings
during a coumarin treatment episode and the number of
patients involved was assessed. For frequently occurring
PID groups, the individual PIDs within this group were
determined. For all patients involved in at least one
potential drug-drug interaction (the ‘‘cases’’), the number
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of different PIDs and the relevance of the exposed potential
interaction(s) were determined.
Results
The study cohort included 76,455 users of mainly aceno-
coumarol in the period 1991–2003 (Table 1). Gender was
equally divided, and about two-thirds of the coumarin-
users were older than 60 years of age. A quarter of the
users had more than 730 days of coumarin treatment
during follow-up.
In total, 48,627 patients or ‘‘cases’’ (64% of all
coumarin-users) were involved in at least one potential
drug interaction during anticoagulant therapy. Gender was
equally divided, and 75% of the cases was older than
60 years of age (Table 2). Multiple potential drug inter-
actions occurred in more than half of the cases; 5% of the
cases were even dispensed eight or more different PIDs.
About 35% of the cases were dispensed a (very) strongly
interacting drug, that necessitates intensive monitoring of
anticoagulation (relevance category 2 and 3). A contrain-
dicated drug (relevance category 1) was dispensed in 3% of
the cases.
The most frequently dispensed PIDs during anticoagu-
lant therapy with coumarins were antibacterial drugs and
non-steroidal anti-inflammatory drugs (NSAIDs), encom-
passing nearly 120,000 antibacterial dispensings in 39% of
all coumarin-users, and almost 127,000 NSAID-dispensings
in 37% of all coumarin-users, respectively (Table 3). The
top three potentially interacting antibacterial drugs were
amoxicillin, doxycycline, and amoxicillin plus clavulanic
acid (dispensed to 13, 13, and 10% of all coumarin-users,
respectively). Diclofenac, ibuprofen, and naproxen were the
three most frequently dispensed NSAIDs (dispensed to 15,
9, and 7% of all coumarin-users, respectively).
Discussion
The results of the present population-based cohort study
show that potential drug interactions with coumarins fre-
quently occur in daily practice. About two-thirds of users
of acenocoumarol or phenprocoumon (50,000 out of
76,000 users) were dispensed at least one PID. In about one
third of these cases, this concerned (very) strongly inter-
acting drugs. The most frequently dispensed PIDs were
NSAIDs.
Although, routine screening for potential interactions is
implemented at all pharmacies in the Netherlands, a
pharmacist may selectively switch off one or more of the
interaction-modules. Consequently, some potential drug-
drug interactions may remain undetected. This may explain
the dispensing of contraindicated drugs (category 1 PIDs)
to 3% of the cases and possibly part of the preferably
Table 1 Characteristics of users of acenocoumarol or phenprocou-






Gender Men 37,767 49.4
Women 38,688 50.6

























Table 2 Demographics and relevance of potential drug interactions
during anticoagulant therapy with coumarins in the period 1991–2004





Gender Men 24,052 49.5
Women 24,575 50.5











Relevancea Category 1 1,574 3.2
Category 2 1,476 3.0
Category 3 14,609 30.0
Category 4 31,846 65.5
Category 5 28,062 57.7
a Numbers do not add up to 100% as patients may have been in-
volved in multiple PIDs of different relevance
PID: potentially interacting drug
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substituted category 3 PIDs dispensed to 30% of the cases.
Category 3 PIDs may not be avoidable due to, for example,
certain patient factors or comorbidity, or lack of prescrip-
tion alternatives. Unfortunately, we did not have this
information. An improved use of the routine screening may
reduce the number of PIDs dispensed. It is yet to be
expected that this reduction will only be limited.
The study encompassed the period 1991–2003. As
mentioned in the methods, the PIDs considered for the
study were based on the current interaction database at the
time the study was performed (i.e., the 2004 version). The
majority of the selected PIDs were already included in this
interaction database before 1991 and were available during
the whole study period. However, eight out of 24 selected
individual drugs (e.g. benzbromarone and disopyramid)
and three out of 11 selected drug groups (non-nucleoside
reverse transcriptase inhibitors, protease inhibitors and
thyreostatics) were included in the interaction database
from 1998 or later, and so were only available during the
second half of the study period. Consequently, the number
of dispensings and patients will be smaller for these drugs.
However, our finding that antibacterial drugs and NSAIDs
are the most frequently dispensed PIDs is still valid; the
number of patients for these two PIDs is much higher than
for the other PIDs.
The type of coumarin mainly used by our study cohort
was acenocoumarol. In many countries, warfarin is the
coumarin of first choice. Potential drug interactions during
anticoagulant therapy with warfarin have been shown to be
a frequent issue, as well [8, 9]. Among 134,833 patients
receiving long-term warfarin therapy, 109,998 (81.6%)
were prescribed a concurrent prescription for at least one
PID [8].
Given the resemblance in the metabolism of acenocou-
marol and warfarin, both types of coumarin are likely to be
sensitive to the same PIDs. However, as the CYP2C9
isoenzyme appears to be less important for the clearance of
acenocoumarol than for the clearance of warfarin,
acenocoumarol may be less sensitive than warfarin [10].
Consequently, the outcome of a drug interaction may be
different for acenocoumarol and warfarin.
Patients on coumarins, who are dispensed a PID, are
exposed to an increased risk of, mainly, bleeding, or
thromboembolism [4]. Bleeding is the most common
Table 3 Frequency of potential drug interactions during anticoagulant therapy with coumarins in the period 1991–2004








Antibacterial drugsa J01, A07AA 4 119,517 30,022 39.3
NSAIDsb M01A, C01EB03, N02BB02, N02BB04, N02BE51, N02BA,
B01AC06, B01AC08, B01AC30
5 126,593 28,364 37.1
Miconazole A07AC01, G01AF04 1 1,706 890 1.2
Amiodarone C01BD01 3 35,387 4,238 5.5
Cotrimoxazole J01EE01, J01EE03 3 7,189 4,087 5.3
SSRIs N06AB 4 31,078 3,380 4.4
Thyreomimetics H03A 3 24,052 2,323 3.0
Allopurinol M04AA01 3 15,943 1,742 2.3
Anti-epileptics (enzyme
inducing)
N03AA, N03AB02, N03AF01, N05CA, N05CB02, L02BG01 2 16,206 1,414 1.8
Cimetidinec A02BA01 3 5,152 931 1.2
Fibrates C10AB 3 8,228 901 1.2
Metronidazole J01XD01,G01AF01, P01AB01 3 1,246 768 1.0
Thyreostatics H03B 3 7,125 751 1.0
* The following PIDs or PID-groups each concerned less than 1.0% of the patients: Androgens (A14A,G03B,G03XA01), Azapropazone
(M01AX04), Azathioprine (L04AX01), Benzbromarone (M04AB03), Bile acid sequestrants (C10AC), Disopyramid (C01BA03), Disulfiram
(N07BB01), Fluconazole (J02AC01-except for single dosages), Griseofulvin (D01BA01), Isoniazid (J04AC01), Itraconazole (J02AC02),
Ketoconazole (J02AB02), Mercaptopurine (L01BB02), Non-nucleoside reverse transcriptase inhibitors (J05AG), Phenylbutazone (M01AA01),
Propafenone (C01BC03), Protease inhibitors (J05AE), Quinidine (C01BA01), Rifampicin (J04AB02,J04AM02), Rifabutin (J04AB04),
Tamoxifen (L02BA01), and Voriconazole (J02AC03)
a exclusive cotrimoxazole and metronidazole; b Exclusive azapropazone and phenylbutazone; c Applies to acenocoumarol only
ATC-code: Anatomical Therapeutic Chemical Classification System - code, WHO Collaborating Centre for Drug Statistics Methodology, ATC/
DDD index 2005 (URL: http://www.whocc.no/atcddd)
NSAID: non-steroidal anti-inflammatory drug; PID: potentially interacting drug; SSRI: selective serotonin reuptake inhibitor
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complication of anticoagulant therapy. Major or life-
threatening hemorrhage during anticoagulant therapy with
coumarins has been shown to occur at an estimated rate of
1.1–3.6 per 100 patient-years [11–13]. Concomitant use of
other drugs is one of the major determinants of bleeding
during anticoagulant therapy [14]. In the present study,
antibacterial drugs and NSAIDs were the main PIDs
dispensed during coumarin therapy. Antibacterial drugs
enhance the anticoagulant effect of coumarins, thereby
increasing the risk of bleeding [15]. In a population-based
cohort study by Visser et al. use of antibacterial drugs was
associated with a 4–20 times increased risk of over anti-
coagulation [16]. The risk of major bleeding associated
with the use of antibacterial drugs, has been shown to be
four to seven times increased [17]. NSAIDs and anti-
thrombotic salicylates mainly increase the risk of bleeding
by interfering with hemostasis by inhibiting platelet func-
tion, or by their ulcerogenic effect [18]. In a previous
study, we found a 2–7 times increased risk of major
bleeding with the use of NSAIDs during anticoagulant
therapy [17]. Although, the risks of major bleeding
increase quite strongly in case of concomitant use of
antibacterial drugs and NSAIDs, absolute incidence rates
are low. Regarding antibacterial drugs an incidence rate of
4.3–7.4 major bleedings per 100 patient-years has been
reported. For NSAIDs this rate was 2.4–7.4 per 100
patient-years [17].
In addition to putting patients at an increased risk, the
high drug interaction potential of coumarins costs time and
money. If at the pharmacy, potential interactions are
detected by the automated computer system, actions have
to be taken before drugs are dispensed. The necessary
action ranges from just informing the anticoagulation clinic
and/or the patient, to consulting the prescribing physician
for a substitute (Dutch standard on coumarin interactions;
available through the internet via URL: http://www.fnt.nl).
In addition, the use of a PID may necessitate intensive
monitoring by the anticoagulation clinic. This concerned
one-third of our cases.
Conclusion
The results of the present population-based cohort study
show that potential drug interactions during anticoagulant
therapy with coumarins frequently occur in daily practice,
confronting about two-third of patients with an increased
risk of, mainly, bleeding. To a large part, this is attributable
to commonly prescribed medication like antibacterial drugs
and NSAIDs. This situation substantiates the need for new
anticoagulants with less drug–drug interactions.
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